Today’s Solutions: January 29, 2022

A new study spearheaded by Professor Sarah Blagden and Dr. Hagen Schwenzer, researchers from the University of Oxford, in collaboration with biopharmaceutical company NuCana, has led to a novel chemotherapy drug that demonstrates significant potency in killing cancer cells.

The new drug, called NUC-7738, is an enhancement of a naturally-occurring nucleoside analog known as Cordycepin (or 3’deoxyadenosine) that is found in the Himalayan fungus Cordyceps Sinensis. This fungus has been used to treat cancers and other inflammatory diseases in traditional Chinese medicine for centuries, however, the drug is rapidly broken down in the bloodstream, rendering what’s left of it to be of minimal use once it reaches the tumor.

To improve the potency of Cordyceps Sinensis, NuCana developed Cordycepin into a clinical therapy, using the new ProTide technology, resulting in a chemotherapy drug with enhanced efficacy.

What is ProTech technology?

ProTech technology is a novel approach for delivering chemotherapy drugs into cancer cells by attaching small chemical groups to nucleoside analogs such as Cordycepin. These are later metabolized once it has reached the patient’s cancer cells, releasing the activated drug. ProTech technology has already been successfully used in FDA-approved drugs to treat infections like Hepatitis C, Ebola, and Covid-19.

The results

Based on the study published in Clinical Cancer Research, NUC-7738 is even more poisonous than Cordycepin to a range of cancer cells.

Currently, NUC-7738 is being assessed by Oxford researchers and partners in Edinburgh and Newcastle in Phase 1 clinical trial NuTide:701, where the drug is being tested on cancer patients with advanced solid tumors that didn’t respond well to conventional treatment. So far, the early results have demonstrated NUC-7738 promising anti-cancer activity and that the drug is well tolerated by patients.

Based on these encouraging results, Phase 2 clinical trials are in the works.

Source study: Clinical Cancer ResearchThe novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase 1 clinical trial

Solutions News Source Print this article
More of Today's Solutions

Brighton passes buzz-worthy law requiring bee bricks

The city of Brighton and Hove in England have introduced a new planning law worth buzzing about—the law requires new buildings to include special bricks that have little nests for solitary bees. The Brighton & ... Read More

This could be the start of the end for drug-resistant bacteria

The increasing occurrence of drug-resistant bacteria is a huge obstacle humans have to overcome to save lives across the globe. Researchers have done all they can to be prepared against this challenge, such as creating ... Read More

Guaranteed income for poor mothers boosts infant brain activity

A new study published in the Proceedings of the National Academy of Sciences, that uses data from the Baby’s First Years study, put forth results that offer a strong argument for the implementation of basic ... Read More

Start a weekly fitness journal to help you maintain motivation

Now that we are nearing the end of the first month of the year, it may be a good time to assess how our new year's resolutions are going. If your goal for the new ... Read More

Scientists use wood waste and water to create sustainable disinfectant

While the use of disinfectants has already been a regular thing for many people when cleaning their homes, the pandemic has called for unprecedented sanitization of our close surroundings.  While good at their job, some ... Read More

Ease menopause by listening to music

Going through menopause can be an extremely challenging time, where the world you’ve known for most of your life is turned upside down. Not every person's experience of menopause is the same, with symptoms ranging ... Read More